Skip to content

Does the published record support advancing this target?

GLP1R is the positive control: its agonists are approved for type 2 diabetes and obesity, so every stage of the record should hold evidence. Every stage does, the knockout mouse only in part. Use it to see what a mature target looks like before you run your own.

localhost · Inflexa Pro

Question: What does the published record show for GLP1R in obesity?

Plan: GLP1R evidence by stage. Steps: Target scope, Evidence by stage, Human genetics, Outcome trials, Label safety.

Findings: Every stage holds evidence; Thyroid C-cell tumors lead the label.

Sessions built from public datasets: PubMed and openFDA evidence on GLP1R.

  • GLP1R agonists approved for obesity
  • 11 placebo-controlled outcome trials
  • 7 of 11 with the whole 95% CI below 1
  • HR 0.80 major cardiovascular events in SELECT
  • 9 warnings on the US label, the first boxed
The plan

How the analysis runs.

Each step is one node of the plan beside it, approved before anything ran.

GLP1R evidence by stage

literature · 5 steps on 3 tracks

Assess GLP1R against the published record, stage by stage, with the gaps called out.

  • T5S1Target scope, completed, depends on no step
  • T5S2Evidence by stage, completed, depends on T5S1
  • T3S1Human genetics, completed, depends on T5S1
  • T3S2Outcome trials, completed, depends on T5S2
  • T6S1Label safety, completed, depends on T5S2
Approved by you
  1. 01

    T5S1

    Target scope

    The run fixes the question first: GLP1R in obesity, a target with approved agonists, so the answer is known and the run can be judged against it.

  2. 02

    T5S2

    Evidence by stage

    It reads the record stage by stage, from the cloned receptor and the knockout mouse to the weight and outcome trials, and cites each stage.

  3. 03

    T3S1

    Human genetics

    A missense variant, Ala316Thr, lowers fasting glucose and type 2 diabetes risk and protects against coronary heart disease.

  4. 04

    T3S2

    Outcome trials

    Eleven placebo-controlled trials of GLP-1 receptor agonists have major adverse cardiovascular events as their primary outcome. It reads each by its confidence interval.

  5. 05

    T6S1

    Label safety

    It reads the US label for semaglutide 2.4 mg through openFDA: nine warnings, the first boxed, each as the label words it.

The evidence

Three chapters from the record.

Each chapter is one thing the record shows, the decision it leads to, and the figure behind it with its source.

01

Seven of eleven outcome trials show fewer cardiovascular events.

Each trial tests one agonist, at its dose and in its population, against placebo. LEADER, SUSTAIN-6, Harmony Outcomes, REWIND, AMPLITUDE-O, SELECT and SOUL found fewer major adverse cardiovascular events with the drug. EXSCEL's interval reached 1, and those of ELIXA, PIONEER 6 and FREEDOM-CVO crossed it. SELECT is the obesity trial: 17,604 adults with cardiovascular disease and overweight or obesity, without diabetes.

The decision

Count a trial as support only when its whole confidence interval sits below 1, and read each result as its drug's: the trials show what these agonists do to cardiovascular risk, and the receptor's own case rests on the stages that follow.

Major cardiovascular events in eleven outcome trials Trial reports on PubMed: PMIDs 26630143, 27295427, 27633186, 28910237, 30291013, 31189511, 31185157, 34215025, 34873344, 37952131 and 40162642
Values in the chart
RowChange in hazard, %
ELIXA2
LEADER−13
SUSTAIN-6−26
EXSCEL−9
Harmony−22
REWIND−12
PIONEER 6−21
AMPLITUDE-O−27
FREEDOM-CVO21
SELECT−20
SOUL−14

Every placebo-controlled trial of a GLP-1 receptor agonist with major adverse cardiovascular events as its primary outcome, published in full by 26 October 2026, in order of publication; trials against another drug, and of dual GIP and GLP-1 agonists, are left out. Change in hazard against placebo, from each hazard ratio with its 95% CI: ELIXA 1.02 (0.89 to 1.17), LEADER 0.87 (0.78 to 0.97), SUSTAIN-6 0.74 (0.58 to 0.95), EXSCEL 0.91 (0.83 to 1.00), Harmony Outcomes 0.78 (0.68 to 0.90), REWIND 0.88 (0.79 to 0.99), PIONEER 6 0.79 (0.57 to 1.11), AMPLITUDE-O 0.73 (0.58 to 0.92), FREEDOM-CVO 1.21 (0.90 to 1.63), SELECT 0.80 (0.72 to 0.90), SOUL 0.86 (0.77 to 0.96). Green where the interval stays below 1. ELIXA and FREEDOM-CVO add hospitalization for unstable angina to the composite, REWIND counts deaths of unknown cause and AMPLITUDE-O deaths of undetermined cause as cardiovascular, and FREEDOM-CVO gave exenatide by continuous subcutaneous infusion.

02

Every stage holds evidence, the knockout only in part.

The receptor was cloned in 1992 and couples GLP-1 to cAMP. Mice without it are glucose intolerant and feed and weigh as usual. A human variant ties it to glucose and the heart, and the trials and the label close the chain.

The decision

Call out the knockout's normal weight as the one gap, and rest the weight evidence on the trials.

GLP1R evidence by stage PubMed abstracts and the US label
StageWhat the record showsSource
ReceptorCloned from rat islets; binds GLP-1 with high affinity and raises cAMPPMID 1326760
Knockout mouseGlucose intolerant, with normal feeding and body weightPMID 8898756
Human geneticsAla316Thr (rs10305492) lowers fasting glucose and type 2 diabetes risk, and protects against coronary heart diseasePMID 27252175
Weight trialSTEP 1: 1,961 adults, body weight down 14.9% at 68 weeks against 2.4% on placeboPMID 33567185
Outcome trialSELECT: 17,604 adults without diabetes, hazard ratio 0.80 for major cardiovascular eventsPMID 37952131
LabelApproved for weight reduction and to cut cardiovascular risk; boxed warning for thyroid C-cell tumorsUS label

One line per stage, each from its source's own abstract or label.

03

The label names its risks, the thyroid first.

The US label for semaglutide 2.4 mg carries a boxed warning for thyroid C-cell tumors, seen in rodents, with human relevance not determined. Primates express little GLP1R on their C-cells (PMID 20203154). Pancreatitis, gallbladder disease and acute kidney injury follow among the warnings.

The decision

Rank label warnings above report counts, and carry the boxed warning into the target's profile.

Warnings on the US label US label for semaglutide 2.4 mg (WEGOVY) via openFDA, version 6, effective 23 April 2024
SectionWarningWhat the label says
Boxed, 5.1Thyroid C-cell tumorsTumors in rodents at clinically relevant exposures; human relevance not determined. Contraindicated with a personal or family history of medullary thyroid carcinoma, or with MEN 2.
5.2Acute pancreatitisSeen in trials. Stop if it is suspected; do not restart if it is confirmed.
5.3Acute gallbladder diseaseCholelithiasis in 1.6% against 0.7% on placebo in adults, and 3.8% against 0% from age 12.
5.4HypoglycemiaA higher risk with insulin or an insulin secretagogue.
5.5Acute kidney injuryPostmarketing reports, some needing dialysis, mostly after nausea, vomiting or diarrhea with volume depletion.
5.6HypersensitivitySerious reactions reported, including anaphylaxis and angioedema.
5.7Diabetic retinopathy complicationsIn type 2 diabetes, 4.0% against 2.7% on placebo.
5.8Heart rate increaseResting heart rate rises on treatment.
5.9Suicidal behavior and ideationReported in trials of other weight management products.

Sections 5.1 to 5.9 of the label, each in brief; 5.1 restates the boxed warning.

More from the record

Two more results from the record.

Each tab is one further result, with its source under its title.

Adults reaching each weight loss at 68 weeks STEP 1 trial report, PMID 33567185
Values in the chart
Weight lostSemaglutide 2.4 mgPlacebo
5% or more86.431.5
10% or more69.112
15% or more50.54.9

1,961 adults with overweight or obesity, without diabetes. Mean change in body weight, 14.9% down on semaglutide 2.4 mg and 2.4% down on placebo.

Findings and the record

What the record shows, and how each result was made.

Each finding names the step it came from and how sure it is. Every file carries a content hash, lineage shows how any figure was made, and the signature shows the record has not changed since.

  • Every stage holds evidence

    confirmed

    Receptor, knockout, genetics and outcome trials each hold evidence; SELECT cut major cardiovascular events by 20%.

    High confidenceT5S2PMID 37952131
  • The knockout keeps its weight

    partially confirmed

    Mice without GLP1R are glucose intolerant but feed and weigh as usual, so the weight evidence rests on the drug trials.

    Medium confidenceT5S2PMID 8898756
  • Thyroid C-cell tumors lead the label

    expected

    A boxed warning from rodent studies; pancreatitis, gallbladder disease and kidney injury follow.

    High confidenceT6S1US label, boxed warning

Illustration

inflexa · prov

$ inflexa prov lineage output/evidence_by_stage.csv

output/evidence_by_stage.csv sha256:5b7e…02c4

t5s2_evidence_by_stage exit 0

output/papers_by_stage.json sha256:c93a…4f18

t5s1_target_scope exit 0

model openai/gpt-6-astra · step T5S2

signed ed25519:2b8d…c51e

$ inflexa prov verify

ok · chain intact · signature valid

The record's shape for this evidence chain, with placeholder hashes. Each file carries its hash and each step its exit code.

Who it is for

For anyone deciding whether to advance a target.

  • Target biology lead

    See how far the published record carries a target, stage by stage, before committing to the studies that would test it.

  • Translational science head

    Identify translational gaps and contradictions that could derail programs, before they become expensive.

  • Portfolio reviewer

    Compare targets by evidence maturity, stage by stage, to allocate resources effectively.

  • Academic researcher

    Read a target's published record and its label before you commit a year to it. No institutional license required.

Start with a question you already have.

Install the CLI and pay nobody but your model provider, open a free Cloud account, or talk to us about Pro for your team.